Efruxifermin is an investigational drug developed by Akero Therapeutics, acting as a fibroblast growth factor 21 analog developed to treat metabolic dysfunction-associated steatohepatitis, formerly known as non-alcoholic steatohepatitis, and type 2 diabetes. From Wikipedia
